Golden
SF17 Therapeutics

SF17 Therapeutics

SF17 Therapeutics is a company founded in 2018 and based in Berkeley, California, that uses analytics and AI to develop precision immune therapies to target autoimmune, auto-inflammatory disease and immune oncology conditions.

SF17 launched in 2018 at a Y Combinator S18 Demo Day, and is now headquartered in San Francisco, California. The founding team for SF17 Therapeutics previously founded Simpatica Medicine. SF17 is one of the startup companies that joined the CITRIS Foundry at UC Berkeley in 2018. 



Through patient monitoring, the SF17 platform allows paediatricians to match patients with patient-specific treatment regimens or regimen changes. The platform is also being used to identify targets for new drug compound development.

Timeline

People

Name
Role
LinkedIn

David Ott

Co-Founder and CTO



Further reading

Title
Author
Link
Type
Date

All 59 startups that launched today at Y Combinator's S18 Demo Day 2

Lucas Matney, Connie Loizos, Jonathan Shieber, Anna Escher, Anthony Ha

Web



Six new startups join the CITRIS Foundry portfolio of science-driven companies

CITRIS Foundry

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References